These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2340793)

  • 1. Longitudinal evaluation of the renal clearance of glycated albumin in the diabetic rat.
    Layton GJ; Allen TJ; Jerums G
    Diabetes Res Clin Pract; 1990 Mar; 8(3):221-6. PubMed ID: 2340793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glycation of albumin on its renal clearance in normal and diabetic rats.
    Layton GJ; Jerums G
    Kidney Int; 1988 Mar; 33(3):673-6. PubMed ID: 3367558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycation of albumin, not glomerular basement membrane, alters permeability in an in vitro model.
    Daniels BS; Hauser EB
    Diabetes; 1992 Nov; 41(11):1415-21. PubMed ID: 1397717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of glycated albumin in insulin-dependent diabetic patients with normal urinary albumin excretion.
    Pagano G; Chiambretti A; Calefato V; Tomalino M; Cecchini G; Bruno A; Cavallo-Perin P
    Acta Diabetol Lat; 1991; 28(1):39-45. PubMed ID: 1862690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation and validation of the affinity chromatography method for measuring glycated albumin in serum and urine.
    Silver AC; Lamb E; Cattell WR; Dawnay AB
    Clin Chim Acta; 1991 Oct; 202(1-2):11-22. PubMed ID: 1807865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycation of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy.
    Bundschuh I; Jäckle-Meyer I; Lüneberg E; Bentzel C; Petzoldt R; Stolte H
    Eur J Clin Chem Clin Biochem; 1992 Oct; 30(10):651-6. PubMed ID: 1493158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy.
    Poduslo JF; Curran GL
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2218-22. PubMed ID: 1549585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of non-enzymatic glycation of serum proteins on their permeation into peripheral nerve in normal and streptozotocin-diabetic rats.
    Patel NJ; Misra VP; Dandona P; Thomas PK
    Diabetologia; 1991 Feb; 34(2):78-80. PubMed ID: 2065852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of variation in turnover of glycated albumin on indices of diabetic control.
    Johnson RN; Easdale RW; Tatnell M; Baker JR
    Clin Chim Acta; 1991 May; 198(3):229-38. PubMed ID: 1889123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal handling of glycated albumin in non-insulin-dependent diabetes mellitus with nephropathy.
    Cha T; Tahara Y; Yamato E; Yoneda H; Ikegami H; Noma Y; Shima K; Ogihara T
    Diabetes Res Clin Pract; 1991 Jul; 12(3):149-56. PubMed ID: 1889345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosyl albumin and diabetic microalbuminuria: demonstration of an altered renal handling.
    Ghiggeri GM; Candiano G; Delfino G; Bianchini F; Queirolo C
    Kidney Int; 1984 Mar; 25(3):565-70. PubMed ID: 6376909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice.
    Cohen MP; Hud E; Shea E; Shearman CW
    Metabolism; 2002 Jul; 51(7):901-5. PubMed ID: 12077739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats.
    Huijberts MS; Wolffenbuttel BH; Crijns FR; Nieuwenhuijzen Kruseman AC; Bemelmans MH; Struijker Boudier HA
    Diabetologia; 1994 Jan; 37(1):10-4. PubMed ID: 8150221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The increase in albuminuria induced by exercise is not associated with preferential excretion of glycated albumin in type 1 (insulin-dependent) diabetic patients.
    Cavallo-Perin P; Chiambretti A; Calefato V; Tomalino M; Urbino R; Cecchini G; Pagano G
    Diabetologia; 1991 Nov; 34(11):813-6. PubMed ID: 1769440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent) diabetes mellitus.
    Kverneland A; Feldt-Rasmussen B; Vidal P; Welinder B; Bent-Hansen L; Søegaard U; Deckert T
    Diabetologia; 1986 Sep; 29(9):634-9. PubMed ID: 3792696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.
    Cohen MP; Sharma K; Jin Y; Hud E; Wu VY; Tomaszewski J; Ziyadeh FN
    J Clin Invest; 1995 May; 95(5):2338-45. PubMed ID: 7738197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential excretion of glycated albumin in C57BL-Ks-J mice: effects of diabetes.
    Kowluru A; Kowluru RA
    Experientia; 1992 May; 48(5):486-8. PubMed ID: 1601114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycated albumin: a marker of glycaemic status in rats with experimental diabetes.
    Neuman RG; Hud E; Cohen MP
    Lab Anim; 1994 Jan; 28(1):63-9. PubMed ID: 8158971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse.
    Cohen MP; Masson N; Hud E; Ziyadeh F; Han DC; Clements RS
    Exp Nephrol; 2000; 8(3):135-43. PubMed ID: 10810230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy.
    Shcheglova T; Makker S; Tramontano A
    J Am Soc Nephrol; 2009 May; 20(5):1012-9. PubMed ID: 19389854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.